

Safety Data Sheet

13 Mix quinolones quality control in pork powder



Version : V2.0.0.1

Report No. : BWS0480-2016-MSDS-EP

Creation Date : 2026/01/16

Revision Date : -

***Prepared in accordance with EU REACH Regulation (REACH 1907/2006 with amendment 2020/878)**

1 Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product Name	13 Mix quinolones quality control in pork powder
Cat No.	BWS0480-2016
CAS No.	Not applicable
EC No.	Not applicable
Molecular Formula	Not applicable
REACH Registration Number	-
UFI	No information available

1.2 Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Please consult manufacturer.
Uses advised against	Please consult manufacturer.

1.3 Details of the supplier of the Safety Data Sheet

Name of the company	Weiyel Inc
Address of the company	Hedian Light Industrial Park, Chengguan Town, Shangcheng County, Xinyang City, Henan Province, China
Post code	465350
Telephone number	010-58103678
Fax number	010-84840368
E-mail address	info@weiyel.com

1.4 Emergency telephone number

Emergency telephone number	010-58103678
Opening hours	24h

2 Hazards identification

2.1 CLP classification according to Regulation (EC) No. 1272/2008 with amendment 2023/707

Acute Toxicity - Oral	Category 4
-----------------------	------------

2.2 Label elements

Hazard pictograms	
Signal word	Warning

Hazard statements

H302	Harmful if swallowed
------	----------------------

Precautionary statements

◆ Prevention

P264	Wash hands and other parts of the body (if related) thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.

◆ Response

P330	Rinse mouth.
P301+P312	IF SWALLOWED: Call a POISON CENTRE/doctor if you feel unwell.

◆ Storage

Storage	Not applicable
---------	----------------

◆ Disposal

P501	Dispose of contents/container in accordance with local/regional/national/international regulations.
------	-----------------------------------------------------------------------------------------------------

2.3 Other hazards

◆ Results of PBT and vPvB assessment

Component	Results of PBT and vPvB assessment [according to (EC) No 1907/2006]
Enrofloxacin	Insufficient information, temporarily unable to evaluate
Ofloxacin	Insufficient information, temporarily unable to evaluate
Norfloxacin	Insufficient information, temporarily unable to evaluate
Danofloxacin	Insufficient information, temporarily unable to evaluate
Difloxacin	Insufficient information, temporarily unable to evaluate
Sarafloxacin	Insufficient information, temporarily unable to evaluate
Ciprofloxacin	Insufficient information, temporarily unable to evaluate
Marbofloxacin	Insufficient information, temporarily unable to evaluate
Oxolinic acid	Insufficient information, temporarily unable to evaluate
Flumequine	Insufficient information, temporarily unable to evaluate
Lomefloxacin	Insufficient information, temporarily unable to evaluate
Pefloxacin	Insufficient information, temporarily unable to evaluate
Enoxacin	Insufficient information, temporarily unable to evaluate

◆ Results of endocrine disrupting properties assessment

Component	Results of endocrine disrupting properties assessment [according to (EU) No 2017/2100 or (EU) No 2018/605]
-----------	------------------------------------------------------------------------------------------------------------

Enrofloxacin	Insufficient information, temporarily unable to evaluate
Ofloxacin	Insufficient information, temporarily unable to evaluate
Norfloxacin	Insufficient information, temporarily unable to evaluate
Danofloxacin	Insufficient information, temporarily unable to evaluate
Difloxacin	Insufficient information, temporarily unable to evaluate
Sarafloxacin	Insufficient information, temporarily unable to evaluate
Ciprofloxacin	Insufficient information, temporarily unable to evaluate
Marbofloxacin	Insufficient information, temporarily unable to evaluate
Oxolinic acid	Insufficient information, temporarily unable to evaluate
Flumequine	Insufficient information, temporarily unable to evaluate
Lomefloxacin	Insufficient information, temporarily unable to evaluate
Pefloxacin	Insufficient information, temporarily unable to evaluate
Enoxacin	Insufficient information, temporarily unable to evaluate

◆ Other

Not applicable.

3 Composition/information on ingredients

3.1 Substance

Not applicable

3.2 Mixture

Component	Weight % content(or range)	Classification according to Regulation (EC) No. 1272/2008 with amendment 2023/707 [CLP]	Specific Conc. Limits, M-factors
Enrofloxacin CAS : 93106-60-6 EC : - Index No. : -	0.0121	Acute Toxicity - Oral, Category 4, H302; Sensitization - skin, Category 1, H317; Sensitization - respiratory, Category 1, H334	-
Ofloxacin CAS : 82419-36-1 EC : - Index No. : -	0.0124	Acute Toxicity - Oral, Category 4, H302; Skin Corrosion/Irritation, Category 2, H315; Serious eye damage/irritation, Category 2, H319; Acute Toxicity - Inhalation, Category 4, H332	-
Norfloxacin CAS : 70458-96-7 EC : - Index No. : -	0.0122	Serious eye damage/irritation, Category 2, H319	-
Danofloxacin CAS : 112398-08-0 EC : - Index No. : -	0.0124	Serious eye damage/irritation, Category 2, H319; Specific target organ toxicity - repeated exposure, Category 2, H373; Hazardous to the aquatic environment - long-term (chronic) hazard, Category 3, H412	-
Difloxacin CAS : 98106-17-3 EC : - Index No. : -	0.0118	No information available	-
Sarafloxacin CAS : 98105-99-8 EC : -	0.012	Not Classified	-

Index No. : -			
Ciprofloxacin CAS : 85721-33-1 EC : - Index No. : -	0.0125	Not Classified	-
Marbofloxacin CAS : 115550-35-1 EC : - Index No. : -	0.0121	Hazardous to the aquatic environment - long-term (chronic) hazard, Category 3, H412	-
Oxolinic acid CAS : 14698-29-4 EC : - Index No. : -	0.0132	Acute Toxicity - Oral, Category 4, H302	-
Flumequine CAS : 42835-25-6 EC : - Index No. : -	0.0138	Not Classified	-
Lomefloxacin CAS : 98079-51-7 EC : - Index No. : -	0.0119	Acute Toxicity - Oral, Category 4, H302; Acute Toxicity - Dermal, Category 4, H312; Acute Toxicity - Inhalation, Category 4, H332	-
Pefloxacin CAS : 70458-92-3 EC : - Index No. : -	0.0119	Acute Toxicity - Oral, Category 4, H302; Skin Corrosion/Irritation, Category 2, H315; Serious eye damage/irritation, Category 2, H319; Specific target organ toxicity - single exposure; respiratory tract irritation, Category 3, H335	-
Enoxacin CAS : 74011-58-8 EC : - Index No. : -	0.0124	Not Classified	-

4 First-aid measures

4.1 Description of first aid measures

General advice	Immediate medical attention is required. Show this safety data sheet (SDS) to the doctor in attendance.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician if feel uncomfortable.
Skin contact	Take off contaminated clothing and shoes immediately. Wash off with plenty of soap and water for at least 15 minutes and consult a physician if feel uncomfortable.
Ingestion	Never give anything by mouth to an unconscious person. Call a physician or Poison Control Center immediately.
Inhalation	Move victim into fresh air. If breathing is difficult, give oxygen. Do not use mouth to mouth resuscitation if victim ingested or inhaled the substance. If not breathing, give artificial respiration and consult a physician immediately.
Protecting of first-aiders	Ensure that medical personnel are aware of the substance involved. Take precautions to protect themselves and prevent spread of contamination.

4.2 Most important symptoms/effects, acute and delayed

1	Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupational exposure.
---	----------------------------------------------------------------------------------------------------------------------------------------

4.3 Indication of any immediate medical attention and special treatment needed

1	Treat symptomatically.
---	------------------------

2	Symptoms may be delayed.
---	--------------------------

5 Fire-fighting measures

5.1 Extinguishing media

Suitable extinguishing media	Use extinguishing media suitable for surrounding area.
Unsuitable extinguishing media	There is no restriction on the type of extinguisher which may be used.

5.2 Specific hazards arising from the substance or mixture

1	Development of hazardous combustion gases or vapor possible in the event of fire.
2	May expansion or decompose explosively when heated or involved in fire.

5.3 Advice for firefighters

1	As in any fire, wear self-contained breathing apparatus (MSHA/NIOSH approved or equivalent) and full protective gear.
2	Fight fire from a safe distance, with adequate cover.
3	Prevent fire extinguishing water from contaminating surface water or the ground water system.

6 Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

1	Ensure adequate ventilation. Remove all sources of ignition. Take precautionary measures against static discharges.
2	Evacuate personnel to safe areas. Keep people away from and upwind of spill/leak.
3	Use personal protective equipment, do not breathe dust/fume.

6.2 Environmental precautions

1	Prevent further leakage or spillage if safe to do so.
2	Discharge into the environment must be avoided.

6.3 Methods and materials for containment and cleaning up

1	Cut off the source of the leak as much as possible.
2	Keep leaks in a ventilated place.
3	Isolation of contaminated areas and restrictions on access.
4	It is recommended that emergency personnel wear dust masks.
5	Collect the spill with a clean shovel and place it in a clean, dry, loosely closed container and move the container away from the leak.
6	Adhered or collected material should be promptly disposed of, in accordance with appropriate laws and regulations.

6.4 Reference to other sections

1	Personal Protective Equipment advice is contained in Section 8 of the SDS.
2	Disposal considerations advice is contained in Section 13 of the SDS.

7 Handling and storage

7.1 Precautions for safe handling

◆ Protective measures

1	Handling is performed in a well ventilated place.
---	---------------------------------------------------

2	Wear suitable protective equipment.
3	Avoid contact with skin and eyes.
◆ Measures to prevent fire	
1	Keep away from heat/sparks/open flames/ hot surfaces.
◆ Measures to prevent aerosol and dust generation	
1	Avoid formation of dust and aerosols.
2	Provide appropriate exhaust ventilation at places where dust is formed.
◆ Advice on general occupational hygiene	
1	Wash hands and face after using the substances.
2	Replace the contaminated clothing immediately.

7.2 Conditions for safe storage, including any incompatibilities

1	Keep containers tightly closed.
2	Keep containers in a dry, cool and well-ventilated place.
3	Keep away from heat/sparks/open flames/hot surfaces.
4	Store away from incompatible materials and foodstuff containers.

7.3 Specific end use(s)

1	In addition to use mentioned in the Section 1.2, unforeseen other specific end uses.
---	--------------------------------------------------------------------------------------

8 Exposure controls/personal protection

8.1 Control parameters

◆ Occupational exposure limit values

Occupational Exposure limit values	No relevant regulations
-------------------------------------------	-------------------------

◆ Biological limit values

Biological limit values	No relevant regulations
--------------------------------	-------------------------

◆ Monitoring methods

1	EN 14042 Workplace atmospheres. Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents.
2	GBZ/T 300 and GBZ/T 160 series standard Determination of toxic substances in workplace air.

◆ Derived No effect level (DNEL)

Component	Route of exposure	DNEL for Workers			
		Acute effects (local)	Acute effects (systemic)	Chronic effects (local)	Chronic effects (systemic)
Enrofloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Ofloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Norfloxacin	Inhalation	No data available	No data available	No data available	No data available

	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Danofloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Difloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Sarafloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Ciprofloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Marbofloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Oxolinic acid	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Flumequine	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Lomefloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Pefloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Enoxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available

◆ Predicted No Effect Concentration (PNEC)

Predicted No Effect Concentration (PNEC)	No information available
------------------------------------------	--------------------------

8.2 Exposure controls

8.2.1 Engineering controls

1	Ensure adequate ventilation, especially in confined areas.
---	------------------------------------------------------------

2	Ensure that eyewash stations and safety showers are close to the workstation location.
3	Use explosion-proof electrical/ventilating/lighting/equipment.
4	Set up emergency exit and necessary risk-elimination area.

8.2.2 Personal protection equipment

General requirement	
Eye protection	Must wear appropriate safety goggles.
Hand protection	Must wear appropriate chemical protective gloves.
Respiratory protection	Must wear appropriate personal respiratory protective equipment.
Skin and body protection	Must wear appropriate chemical protective clothing and chemical resistant shoes.

8.2.3 Environmental exposure controls

Environmental exposure controls	No information available
---------------------------------	--------------------------

9 Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	Colorless powdery solid
Colour	Colorless powdery solid
Odor	No information available
Odor threshold	No information available
pH	No information available
Melting point/freezing point(°C)	219 (Enrofloxacin)
Initial boiling point and boiling range(°C)	No information available
Flash point(Closed cup, °C)	Not applicable
Evaporation rate	Not applicable
Flammability	No information available
Upper/lower explosive limits[%(v/v)]	Upper limit : No information available ; Lower limit : No information available
Vapor pressure	Not applicable
Vapor density(Air = 1)	> 1 (Enrofloxacin)
Relative density(Water=1)	No information available
Solubility	Partly miscible with water (Enrofloxacin)
n-octanol/water partition coefficient	No information available
Auto-ignition temperature(°C)	No information available
Decomposition temperature(°C)	No information available
Kinematic viscosity	Not applicable
Explosive properties	No information available
Oxidizing properties	No information available
Particle characteristics	No information available

9.2 Other information

9.2.1 Information with regard to physical hazard classes

Information with regard to physical hazard classes	No information available
----------------------------------------------------	--------------------------

9.2.2 Other safety characteristics

Other safety characteristics	No information available
------------------------------	--------------------------

10 Stability and reactivity

Stability and reactivity

10.1 Reactivity	Contact with incompatible substances can cause decomposition or other chemical reactions.
10.2 Chemical stability	Stable under proper operation and storage conditions.
10.3 Possibility of hazardous reactions	No information available.
10.4 Conditions to avoid	Incompatible materials, heat, flame and spark.
10.5 Incompatible materials	No information available.
10.6 Hazardous decomposition products	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

11 Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008 with amendment 2023/707

13 Mix quinolones quality control in pork powder

Skin corrosion/irritation	Based on available data, the classification criteria are not met
Serious eye damage/irritation	Based on available data, the classification criteria are not met
Skin sensitization	Based on available data, the classification criteria are not met
Respiratory sensitization	Based on available data, the classification criteria are not met
Reproductive toxicity	Based on available data, the classification criteria are not met
STOT-single exposure	Based on available data, the classification criteria are not met
STOT-repeated exposure	Based on available data, the classification criteria are not met
Aspiration hazard	Based on available data, the classification criteria are not met
Germ cell mutagenicity	Based on available data, the classification criteria are not met

Acute toxicity

Component	LD ₅₀ (oral)	LD ₅₀ (dermal)	LC ₅₀ (inhalation,4h)
Oxolinic acid	525mg/kg(Rat)	> 2000mg/kg(Rat)	No information available

Carcinogenicity

Component	List of carcinogens by the IARC Monographs	Report on Carcinogens by NTP
Enrofloxacin	Not Listed	Not Listed
Ofloxacin	Not Listed	Not Listed
Norfloxacin	Not Listed	Not Listed
Danofloxacin	Not Listed	Not Listed

Difloxacin	Not Listed	Not Listed
Sarafloxacin	Not Listed	Not Listed
Ciprofloxacin	Not Listed	Not Listed
Marbofloxacin	Not Listed	Not Listed
Oxolinic acid	Not Listed	Not Listed
Flumequine	Not Listed	Not Listed
Lomefloxacin	Not Listed	Not Listed
Pefloxacin	Not Listed	Not Listed
Enoxacin	Not Listed	Not Listed

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Component	Endocrine disrupting properties
Enrofloxacin	No information available
Ofloxacin	No information available
Norfloxacin	No information available
Danofloxacin	No information available
Difloxacin	No information available
Sarafloxacin	No information available
Ciprofloxacin	No information available
Marbofloxacin	No information available
Oxolinic acid	No information available
Flumequine	No information available
Lomefloxacin	No information available
Pefloxacin	No information available
Enoxacin	No information available

11.2.2 Other Information

Other Information	See Section 11.1
--------------------------	------------------

12 Ecological information

12.1 Toxicity

Acute aquatic toxicity

Acute aquatic toxicity	No information available
-------------------------------	--------------------------

Chronic aquatic toxicity

Chronic aquatic toxicity	No information available
---------------------------------	--------------------------

12.2 Persistence and degradability

Persistence and degradability	No information available
--------------------------------------	--------------------------

12.3 Bioaccumulative potential

Bioaccumulative potential	No information available
----------------------------------	--------------------------

12.4 Mobility in soil

Mobility in soil	No information available
-------------------------	--------------------------

12.5 Results of PBT and vPvB assessment

Component	Results of PBT and vPvB assessment [according to (EC) No 1907/2006]
Enrofloxacin	Insufficient information, temporarily unable to evaluate
Ofloxacin	Insufficient information, temporarily unable to evaluate
Norfloxacin	Insufficient information, temporarily unable to evaluate
Danofloxacin	Insufficient information, temporarily unable to evaluate
Difloxacin	Insufficient information, temporarily unable to evaluate
Sarafloxacin	Insufficient information, temporarily unable to evaluate
Ciprofloxacin	Insufficient information, temporarily unable to evaluate
Marbofloxacin	Insufficient information, temporarily unable to evaluate
Oxolinic acid	Insufficient information, temporarily unable to evaluate
Flumequine	Insufficient information, temporarily unable to evaluate
Lomefloxacin	Insufficient information, temporarily unable to evaluate
Pefloxacin	Insufficient information, temporarily unable to evaluate
Enoxacin	Insufficient information, temporarily unable to evaluate

12.6 Endocrine disrupting properties

Component	Endocrine disrupting properties
Enrofloxacin	No information available
Ofloxacin	No information available
Norfloxacin	No information available
Danofloxacin	No information available
Difloxacin	No information available
Sarafloxacin	No information available
Ciprofloxacin	No information available
Marbofloxacin	No information available
Oxolinic acid	No information available
Flumequine	No information available
Lomefloxacin	No information available
Pefloxacin	No information available
Enoxacin	No information available

12.7 Other adverse effects

	No information available
--	--------------------------

13 Disposal considerations

13.1 Waste treatment methods

Waste chemicals	Before disposal should refer to the relevant national and local laws and regulation. Recommend the use of incineration disposal.
Contaminated packaging	Containers may still present chemical hazard when empty. Keep away from hot and ignition source of fire. Return to supplier for recycling if possible.
Disposal recommendations	Refer to section waste chemicals and contaminated packaging.

14 Transport information

Label and Mark

Transporting Label	Not applicable
--------------------	----------------

IMDG-CODE

IMDG-CODE	NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS
-----------	------------------------------------------------

IATA-DGR

IATA-DGR	NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS
----------	------------------------------------------------

UN-ADR

UN-ADR	NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS
--------	------------------------------------------------

Special precautions for user

	Transport vehicles should be equipped with the appropriate variety and quantity of fire equipment and emergency equipment leakage during transport. Before transport, should be preceded by checking whether container integrity, sealing. The transport unit must be placarded and marked in accordance with relevant transporting requirements.
--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Maritime transport in bulk according to IMO instruments

- ◆ Transport in bulk according to Annex II of MARPOL and the IBC code

	Not Available
--	---------------

- ◆ Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

	Not Available
--	---------------

- ◆ Transport in bulk in accordance with the IGC Code

	Not Available
--	---------------

15 Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

International chemical inventory

Component	A	B	C	D	E	F	G	H	I	J	K	L	M
Enrofloxacin	√	×	×	×	√	×	√	×	×	×	√	√	√
Ofloxacin	√	×	×	×	×	×	√	×	×	×	√	√	√
Norfloxacin	√	√	×	√	×	√	√	×	×	×	√	√	√
Danofloxacin	×	×	×	×	×	×	×	×	×	×	×	√	√

Difloxacin	x	x	x	x	x	x	x	x	x	x	x	x	√	x
Sarafloxacin	x	x	x	x	x	x	x	x	x	x	x	x	x	√
Ciprofloxacin	√	x	x	x	x	x	x	x	x	x	√	√	√	
Marbofloxacin	x	x	x	x	√	x	x	x	√	x	x	√	√	
Oxolinic acid	x	√	x	√	√	x	√	x	√	√	x	√	√	
Flumequine	x	√	x	x	x	x	√	x	x	x	x	√	√	
Lomefloxacin	x	x	x	x	x	x	x	x	x	x	x	x	x	√
Pefloxacin	x	√	x	x	x	x	x	x	x	x	x	x	x	√
Enoxacin	x	x	x	x	x	x	√	x	x	x	x	x	x	√

- [A]** China Inventory of Existing Chemical Substances(IECSC)
[B] European Inventory of Existing Commercial Chemical Substances(EC inventory)
[C] United States Toxic Substances Control Act Inventory(TSCA)
[D] Canadian Domestic Substances List(DSL)
[E] New Zealand Inventory of Chemicals(NZIoC)
[F] Philippines Inventory of Chemicals and Chemical Substances(PICCS)
[G] Korea Existing Chemicals Inventory(KECL)
[H] Australian. Inventory of Industrial Chemical (AIICS)
[I] Japan Inventory of Existing & New Chemical Substances(ENCS)
[J] Thailand Existing Chemicals Inventory(TECI)
[K] Mexico National Inventory of Chemical Substances (INSQ)
[L] Russia Inventory of Existing Substances (DRAFT)
[M] Inventory of Existing Chemical Substances in Taiwan, China (TCSI)

| List of Chemical Substances under International Conventions

Component	A	B	C
Enrofloxacin	x	x	x
Ofloxacin	x	x	x
Norfloxacin	x	x	x
Danofloxacin	x	x	x
Difloxacin	x	x	x
Sarafloxacin	x	x	x
Ciprofloxacin	x	x	x
Marbofloxacin	x	x	x
Oxolinic acid	x	x	x
Flumequine	x	x	x
Lomefloxacin	x	x	x
Pefloxacin	x	x	x
Enoxacin	x	x	x

- [A]** The Montreal Protocol on Substances that Deplete the Ozone Layer
[B] Stockholm Convention on Persistent Organic Pollutants (POPs)
[C] Rotterdam Convention on the prior informed consent procedure for certain hazardous chemicals and pesticides in international trade

| European chemical inventory

Component	A	B	C	D	E	F	G	H	I
Enrofloxacin	x	x	x	√	x	x	x	x	x
Ofloxacin	x	x	x	x	x	x	x	x	x
Norfloxacin	x	x	x	√	x	x	x	x	x
Danofloxacin	x	x	x	x	x	x	x	x	x
Difloxacin	x	x	x	x	x	x	x	x	x
Sarafloxacin	x	x	x	x	x	x	x	x	x
Ciprofloxacin	x	x	x	√	x	x	x	x	x
Marbofloxacin	x	x	x	x	x	x	x	x	x
Oxolinic acid	x	x	x	√	x	x	x	x	x
Flumequine	x	x	x	√	x	x	x	x	x
Lomefloxacin	x	x	x	√	√	x	x	x	x
Pefloxacin	x	x	x	√	x	x	x	x	x
Enoxacin	x	x	x	x	x	x	x	x	x

- [A] Candidate list of Substances of Very High Concern for authorization under EU REACH regulation
[B] Substances requiring authorisation under EU REACH regulation
[C] Substances restricted under EU REACH
[D] Pre-registered substances under EU REACH
[E] Registered substances under EU REACH
[F] Substance Evaluation – CoRAP under EU REACH
[G] List of priority substances under EU water policy (Directive 2455/2001/EC)
[H] Substances subject to POPs Regulation
[I] Substances proposed as POPs

Note:

- “√” Indicates that the substance included in the regulations.
“x” No data or not included in the regulations.

German water hazard class(WGK)

Component	WGK	Remark
Ofloxacin	WGK 3	
Ciprofloxacin	WGK 2	

- [WGK 1] slightly hazardous to water
[WGK 2] obviously hazardous to water
[WGK 3] highly hazardous to water
[nwg] non-hazardous to water
[awg] hazardous to water in general

German technical instructions on air quality control(TA LUFT)

No information available

German technical rules for hazardous substances(TRGS)

No information available

15.2 Chemical safety assessment

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier.

16 Other information

Information on revision

Creation Date	2026/01/16
Revision Date	-
Reason for revision	-

Reference

- [1] IPCS: The International Chemical SafetyCards (ICSC), website: <http://www.ilo.org/dyn/icsc/showcard.home>.
- [2] IARC, website: <http://www.iarc.fr/>.
- [3] OECD: The Global Portal to Information on Chemical Substances, website: <https://www.echemportal.org/echemportal/>.
- [4] CAMEO Chemicals, website: <http://cameochemicals.noaa.gov/search/simple>.
- [5] NLM: ChemIDplus, website: <http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp>.
- [6] EPA: Integrated Risk Information System, website: <http://cfpub.epa.gov/iris/>.
- [7] U.S. Department of Transportation: ERG, website: <http://www.phmsa.dot.gov/hazmat/library/erg>.
- [8] Germany GESTIS-database on hazard substance, website: <http://gestis-en.itrust.de/>.

Abbreviations and acronyms

CAS	Chemical Abstracts Service	UN	The United Nations
PC-STEL	Short term exposure limit	OECD	Organization for Economic Co-operation and Development
PC-TWA	Time Weighted Average	IMDG-CODE	International Maritime Dangerous Goods CODE
MAC	Maximum Allowable Concentration	IARC	International Agency for Research on Cancer
DNEL	Derived No Effect Level	ICAO	International Civil Aviation Organization
PNEC	Predicted No Effect Concentration	IATA	International Air Transportation Association
NOEC	No Observed Effect Concentration	ACGIH	American Conference of Governmental Industrial Hygienists
LC ₅₀	Lethal Concentration 50%	NFPA	National Fire Protection Association
LD ₅₀	Lethal Dose 50%	NTP	National Toxicology Program
EC ₅₀	Effective Concentration 50%	PBT	Persistent, Bioaccumulative, Toxic
EC _x	Effective Concentration X%	vPvB	very Persistent, very Bioaccumulative
P _{OW}	Partition coefficient Octanol: Water	CMR	Carcinogens, mutagens or substances toxic to reproduction
BCF	Bioconcentration factor	RPE	Respiratory Protective Equipment
ED	Endocrine disruptor		

Disclaimer

This Safety Data Sheet (SDS) was prepared according to REACH Regulation. The data included was derived from international authoritative database and provided by the enterprise. Other information was based on the present state of our knowledge. We try to ensure the correctness of all information. However, due to the diversity of information sources and the limitations of our knowledge, this document is only for user's reference. Users should make their independent judgment of suitability of this information for their particular purposes. We do not assume responsibility for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the product.